Characterisation of C5a receptor agonists from phage display libraries

被引:11
作者
Cain, SA [1 ]
Higginbottom, A [1 ]
Monk, PN [1 ]
机构
[1] Univ Sheffield, Sch Med, Acad Neurol Unit, Sheffield S10 2RX, S Yorkshire, England
关键词
complement receptor; phage display; random mutagenesis; pyrimidine analogue; PCR; 8-oxodeoxyguanosine;
D O I
10.1016/S0006-2952(03)00473-8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
C5a des-Arg(74) has a 10- to 100-fold lower receptor binding affinity than intact C5a and is only a partial agonist. We have used phage display selection from randomly mutated C5a des-Arg74 libraries to isolate variant proteins that can activate C5a receptors with similar potency to C5a. Here we explore the interactions of three variants (V1-3) with C5aR mutated at residues involved in the differential response. The mutant Asp(282)Arg-C5aR is preferentially activated by C5a des-Arg74, probably due to repulsion between Arg(74) of C5a and the substituent Arg(282). In accordance with this hypothesis, V2 (with a polar C-terminus which has no Arg residue) but not V1 (with a C-terminal Arg residue at position 73) could activate Asp(282)Arg-C5aR. V3, with a very hydrophobic C-terminus, was the most potent agonist at Asp(282)Arg-C5aR. Arg(175) is a potential counterion for the C-terminal carboxylate of C5a. C5aR mutated to either Ala or Asp at this position lost nearly all responsiveness to both C5a and C5a des-Arg(74), suggesting that mutation of Arg(175) caused a non-specific loss of receptor conformation and a loss of signalling capacity. However, V3 could still activate Arg(175)Asp/Ala-C5aR with the same potency as wild-type C5aR. demonstrating that the mutant receptors retained high signalling capability and showed a specific loss of responsiveness. Thus C5a des-Arg(74) variants produced by phage display are potentially useful tools for the dissection of ligand-receptor interactions. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:1833 / 1840
页数:8
相关论文
共 27 条
[11]  
Heller T, 1999, J IMMUNOL, V163, P985
[12]   A detailed analysis of the C5a anaphylatoxin effector domain:: selection of C5a phage libraries on differentiated U937 cells [J].
Hennecke, M ;
Otto, A ;
Baensch, M ;
Kola, A ;
Bautsch, W ;
Klos, A ;
Köhl, J .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1998, 252 (01) :36-44
[13]   A selection system to study C5a-C5a-receptor interactions: Phage display of a novel C5a anaphylatoxin, Fos-C5a(Ala27) [J].
Hennecke, M ;
Kola, A ;
Baensch, M ;
Wrede, A ;
Klos, A ;
Bautsch, W ;
Kohl, J .
GENE, 1997, 184 (02) :263-272
[14]   Analysis of the C5a anaphylatoxin core domain using a C5a phage library selected on differentiated U937 cells [J].
Kola, A ;
Baensch, M ;
Bautsch, W ;
Klos, A ;
Köhl, J .
MOLECULAR IMMUNOLOGY, 1999, 36 (02) :145-152
[15]   IDENTIFICATION OF RECEPTOR-BINDING RESIDUES IN THE INFLAMMATORY COMPLEMENT PROTEIN-C5A BY SITE-DIRECTED MUTAGENESIS [J].
MOLLISON, KW ;
MANDECKI, W ;
ZUIDERWEG, ERP ;
FAYER, L ;
FEY, TA ;
KRAUSE, RA ;
CONWAY, RG ;
MILLER, L ;
EDALJI, RP ;
SHALLCROSS, MA ;
LANE, B ;
FOX, JL ;
GREER, J ;
CARTER, GW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (01) :292-296
[16]  
MONK PN, 1994, BIOCHEM MOL BIOL INT, V32, P13
[17]   MUTATION OF GLUTAMATE-199 OF THE HUMAN C5A RECEPTOR DEFINES A BINDING-SITE FOR LIGAND DISTINCT FROM THE RECEPTOR N-TERMINUS [J].
MONK, PN ;
BARKER, MD ;
PARTRIDGE, LJ ;
PEASE, JE .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (28) :16625-16629
[18]   Pharmacological characterization of antagonists of the C5a receptor [J].
Paczkowski, NJ ;
Finch, AM ;
Whitmore, JB ;
Short, AJ ;
Wong, AK ;
Monk, PN ;
Cain, SA ;
Fairlie, DP ;
Taylor, SM .
BRITISH JOURNAL OF PHARMACOLOGY, 1999, 128 (07) :1461-1466
[19]   Site-directed mutagenesis of conserved charged residues in the helical region of the human C5a receptor - Arg206 determines high-affinity binding sites of C5a receptor [J].
Raffetseder, U ;
Roper, D ;
Mery, L ;
Gietz, C ;
Klos, A ;
Grotzinger, J ;
Wollmer, A ;
Boulay, F ;
Kohl, J ;
Bautsch, W .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1996, 235 (1-2) :82-90
[20]   Recombinant human complement C5A receptor antagonist reduces infarct size after surgical revascularization [J].
Riley, RD ;
Sato, H ;
Zhao, ZQ ;
Thourani, VH ;
Jordan, JE ;
Fernandez, AX ;
Ma, XL ;
Hite, DR ;
Rigel, DE ;
Pellas, TC ;
Peppard, J ;
Bill, KA ;
Lappe, RW ;
Vinten-Johansen, J .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2000, 120 (02) :350-358